Alphyn Biologics (Alphyn) is a privately held limited liability company.  Alphyn has an experienced, successful international leadership team and exceptional operational partners and advisory boards that include key thought leaders, researchers, and practitioners in dermatology, skin diseases, infectious disease, oncology, regulatory approvals, and the life science and consumer industries.

Alphyn recently closed its first round of outside financing, raising funds from private investors with medical, life science industry, and legal backgrounds.  Alphyn used the proceeds from this first financing for projects needed to complete its successful FDA Pre-IND meeting, FDA Safety Data Review meeting, formulation work completing final drug product formula, quality control test method and product performance verifications and advancing its in-vitro product testing projects needed to begin its Phase 2 human clinical trial program for its first product to treat Atopic Dermatitis (Eczema), including its drug resistant  bacteria causes.

The company is readying its second round of financing, which will be used to complete the projects necessary to submit the FDA Investigational New Drug Application (IND) to start the Phase 2 human clinical trial.

If you are interested in learning more about Alphyn, or for financial or investment inquiries, please contact Neal Koller at +1 (410) 690-8687 or use the form below: